cyclosporine G in a pharmaceutically acceptable carrier, wherein the cyclosporine G is administered in an amount of from 10 to 100 mg/ml in a medically suitable vehicle.

4. The method of claim **3**, wherein the ocular disease which is treated is selected from the group consisting of endogenous uveitis, Behcet's Disease, corneal transplantation, vernal keratoconjunctivitis, ligneous keratoconjunctivitis, dry eye syndrome, anterior uveitis and onchocerciasis.

5. A method for treating ocular disease which comprises administering to a patient by periocular injection cyclosporine A in a pharmaceutically acceptable carrier, wherein the cyclosporine A is administered in an amount of from 10 to 100 mg/ml in a medically suitable vehicle.

6. The method of claim **5**, wherein the ocular disease which is treated is selected from the group consisting of endogenous uveitis, Behcet's Disease, corneal transplantation, vernal keratoconjunctivitis, ligneous keratoconjunctivitis, dry eye syndrome, anterior uveitis and onchocerciasis.

7. The method of claim **3**, wherein the cyclosporine G is administered in an amount of from 50 to 100 mg/ml in a medically suitable vehicle.

8. The method of claim **5**, wherein the cyclosporine A is administered in an amount of from 50 to 100 mg/ml in a medically suitable vehicle.

9. The method of claim **3**, wherein the dosage range is from about 50 to 200 mg.

10. The method of claim **5**, wherein the dosage range is from about 50 to 200 mg.

11. The method of claim **3**, wherein the medically suitable vehicle is liposomes or water suspensions.

12. The method of claim **5**, wherein the medically suitable vehicle is liposomes or water suspensions.

13. A pharmaceutical composition for treating ocular disease which comprises cyclosporine G or A and a pharmaceutical carrier suitable for periocular injection.

14. The pharmaceutical composition of claim **13**, wherein said cyclosporine is cyclosporine G.

15. The pharmaceutical composition of claim **13**, wherein said cyclosporine is cyclosporine A.

16. The pharmaceutical composition of claim **13**, wherein said pharmaceutical carrier is liposomes or a water suspension.

* * * * *